Add to ORKGThere are errors in the ninth and tenth sentences of the Abstract. These sentences should read: Also there was a decrease in the risk of progression (RR of PFS: 0.82 IC 0.73–0.92) compared to placebo. Conclusions: We observed significant differences in physiologic and clinically relevant outcomes such as reduction in all-cause mortality, IPF related mortality, worsening of IPF and improvement of PFS. So pirfenidone treatment should be considered not only for its benefits in pulmonary function tests but also by its clinically relevant outcomes. There are multiple errors in the Results described below. The third and fourth sentences of the “Progression-free Survival (PFS) ” section should read: The meta-analysis includes 786 patients in inter...
Following publication of the original article [1], the authors notified us of a few requested editio...
Figure 3 in the original article [1] is incorrect; labels for secondary outcomes have been shifted a...
Background and objective: Pirfenidone is an oral antifibrotic agent that is approved in several coun...
Correction : The authors of the above-mentioned paper would like to make the following adjustments t...
Abe M, Tsushima K, Sakayori M, et al. Drug Des Devel Ther. 2018;12:3369–3375.On page 3372...
After publication of our article [1], we have been notified that an extra alpha symbol (α) was mista...
The original version of this article unfortunately contained a mistake. Section “Results”, second pa...
In the original article there was an error. The survival numbers were incorrect. A correction has be...
In the original article, there was a mistake in Table 1 as published. Reference citation [34] was w...
After publication of the Original research article [1] it was brought to our attention that the sent...
In the original publication [1] is an incorrect sentence in the abstract under Conclusions
No abstract available. Article truncated at 150 words. Idiopathic pulmonary fibrosis is a chronic, p...
Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes Vincent...
\ua9 2023, The Author(s).In the sentences beginning ‘At baseline,…’ and ‘The reduction of early morn...
Figure 3 (Meta‑analysis of studies comparing the impact on hyponatremia occurrence of isotonic versu...
Following publication of the original article [1], the authors notified us of a few requested editio...
Figure 3 in the original article [1] is incorrect; labels for secondary outcomes have been shifted a...
Background and objective: Pirfenidone is an oral antifibrotic agent that is approved in several coun...
Correction : The authors of the above-mentioned paper would like to make the following adjustments t...
Abe M, Tsushima K, Sakayori M, et al. Drug Des Devel Ther. 2018;12:3369–3375.On page 3372...
After publication of our article [1], we have been notified that an extra alpha symbol (α) was mista...
The original version of this article unfortunately contained a mistake. Section “Results”, second pa...
In the original article there was an error. The survival numbers were incorrect. A correction has be...
In the original article, there was a mistake in Table 1 as published. Reference citation [34] was w...
After publication of the Original research article [1] it was brought to our attention that the sent...
In the original publication [1] is an incorrect sentence in the abstract under Conclusions
No abstract available. Article truncated at 150 words. Idiopathic pulmonary fibrosis is a chronic, p...
Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes Vincent...
\ua9 2023, The Author(s).In the sentences beginning ‘At baseline,…’ and ‘The reduction of early morn...
Figure 3 (Meta‑analysis of studies comparing the impact on hyponatremia occurrence of isotonic versu...
Following publication of the original article [1], the authors notified us of a few requested editio...
Figure 3 in the original article [1] is incorrect; labels for secondary outcomes have been shifted a...
Background and objective: Pirfenidone is an oral antifibrotic agent that is approved in several coun...